Tackling Issues Observed during the Development of a Liquid Chromatography Method for Small Molecule Quantification in Antibody-Chelator Conjugate
Molecules · 2023
DOI: 10.3390/molecules28062626 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Thomas Bouvarel und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, University of Geneva, CMU-Rue Michel Servet 1, 1211 Geneva, Switzerland. Hauptthemen laut MEDLINE: Immunoconjugates. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer AG.
Abstract (Originalsprache)
In the context of targeted radionuclide therapy, antibody-chelator conjugates (ACCs) are an evolving class of antibody-related drugs with promising applications as tumor-targeted pharmaceuticals. Generally, a typical ACC consists of a recombinant monoclonal antibody (mAb) coupled to radionuclide via a chelating agent. Characterizing the ACC structure represents an analytical challenge since various impurities must be constantly monitored in the presence of formulation components during the quality control (QC) process. In this contribution, a reliable method devoted to the monitoring of an ACC sample, and its small molecule-related synthesis impurities, has been developed via liquid chromatography (LC). A problem-solving approach of common analytical issues was used to highlight some major issues encountered during method development. This included separation of poorly retained impurities (issue #1); interferences from the formulation components (issue #2); analysis of impurities in presence of ACC at high concentration (issue #3); and recovery of impurities during the whole analytical procedure (issue #4). To the best of our knowledge, this is the first time that a chromatographic method for the analysis of ACC synthesis impurities is presented. In addition, the developed approach has the potential to be more widely applied to the characterization of similar ACCs and other antibody-related drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, University of Geneva, CMU-Rue Michel Servet 1, 1211 Geneva, Switzerland.
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU-Rue Michel Servet 1, 1211 Geneva, Switzerland.
- Bayer AG, 42096 Wuppertal, Germany.
ORCID-Profile: Thomas Bouvarel, Valentina D'Atri, Davy Guillarme
Förderung
- Bayer AG
Zitieren
APA
Bouvarel, T., Bremeyer, N., Gao, M., Holkenjans, W., Hetzel, T., Pell, R., D'Atri, V., & Guillarme, D. (2023). Tackling Issues Observed during the Development of a Liquid Chromatography Method for Small Molecule Quantification in Antibody-Chelator Conjugate. Molecules. https://doi.org/10.3390/molecules28062626
Vancouver
Bouvarel T, Bremeyer N, Gao M, Holkenjans W, Hetzel T, Pell R, et al. Tackling Issues Observed during the Development of a Liquid Chromatography Method for Small Molecule Quantification in Antibody-Chelator Conjugate. Molecules. 2023. doi:10.3390/molecules28062626
BibTeX
@article{Bouvarel2023,
author = {Bouvarel, Thomas and Bremeyer, Nadine and Gao, Mimi and Holkenjans, Wiebke and Hetzel, Terence and Pell, Reinhard and D'Atri, Valentina and Guillarme, Davy},
title = {Tackling Issues Observed during the Development of a Liquid Chromatography Method for Small Molecule Quantification in Antibody-Chelator Conjugate},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28062626}
}
EUVIMED